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Abstract: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations of the
GLA gene that result in a deficiency of the enzymatic activity of α-galactosidase A and consequent
accumulation of glycosphingolipids in body fluids and lysosomes of the cells throughout the body.
GB3 accumulation occurs in virtually all cardiac cells (cardiomyocytes, conduction system cells,
fibroblasts, and endothelial and smooth muscle vascular cells), ultimately leading to ventricular
hypertrophy and fibrosis, heart failure, valve disease, angina, dysrhythmias, cardiac conduction
abnormalities, and sudden death. Despite available therapies and supportive treatment, cardiac
involvement carries a major prognostic impact, representing the main cause of death in FD. In the last
years, knowledge has substantially evolved on the pathophysiological mechanisms leading to cardiac
damage, the natural history of cardiac manifestations, the late-onset phenotypes with predominant
cardiac involvement, the early markers of cardiac damage, the role of multimodality cardiac imaging
on the diagnosis, management and follow-up of Fabry patients, and the cardiac efficacy of available
therapies. Herein, we provide a comprehensive and integrated review on the cardiac involvement of
FD, at the pathophysiological, anatomopathological, laboratory, imaging, and clinical levels, as well
as on the diagnosis and management of cardiac manifestations, their supportive treatment, and the
cardiac efficacy of specific therapies, such as enzyme replacement therapy and migalastat.
Keywords: Fabry disease; heart; cardiomyopathy; enzyme replacement therapy; migalastat
1. Fabry Disease Overview
Fabry disease (FD) (OMIM 301500) is a rare lysosomal storage disorder caused by mu-
tations in the GLA gene, leading to deficiency of the enzymatic activity of α-galactosidase
A. Globotriaosylceramide (GB3) and other neutral glycosphingolipids consequently ac-
cumulate in body fluids and lysosomes of cells throughout the body, including in those
that are particularly relevant for the disease, such as in the heart (cardiomyocytes, conduc-
tion system cells, vascular endothelial and smooth muscle cells, and fibroblasts), kidney
(podocytes, tubular, glomerular, mesangial, and interstitial cells), nervous system (neu-
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rons in autonomic and posterior root ganglia) and vascular endothelium and smooth
muscle [1,2].
GLA mutations causing a virtually null enzymatic activity (<5% of the normal mean)
are associated with severe and early onset classical phenotypes, which are characterized
by the development of clinical manifestations in childhood or adolescence, such as acro-
paresthesias, neuropathic pain, hypohidrosis, heat, cold and exercise intolerance, cornea
verticillata, angiokeratomas, gastrointestinal symptoms, and proteinuria. In adulthood,
patients may also suffer from cardiomyopathy, heart failure, dysrhythmias, cardiac con-
duction blocks, renal failure, brain white matter lesions, cerebrovascular events, and
sensorineural deafness. In contrast, GLA mutations leading to a residual enzymatic activity
are associated to attenuated and late-onset phenotypes, which are characterized by the
development of cardiac, renal and/or cerebrovascular manifestations in adulthood [2–5].
In this X-linked disorder, heterozygote females are not merely carriers and their clinical
spectrum widely ranges from asymptomatic to full-blown disease as severe as in affected
males [6,7].
2. Cardiac Involvement in FD
2.1. Pathophysiology
FD leads to GB3 accumulation in virtually all cardiac cells, but the mechanisms
by which substrate accumulation leads to cellular dysfunction or organ damage remain
less defined [8]. GB3 accumulation may affect mitochondrial function, either directly
through accumulation within the mitochondrial membrane or indirectly by preventing
mitophagy [9], likely contributing to the reduction in the activities of the respiratory chain
enzymes that has been shown in fibroblasts [10]. On the other hand, substrate accumulation
and organelle damage have also been shown to induce oxidative stress [9,11]. GB3 has
also been demonstrated to promote a higher proinflammatory cytokine production and
expression [12], to mediate apoptosis [13,14], and to induce endothelial dysfunction [15].
Lyso-GB3, a deacylation product of GB3 [16], has also been shown to inhibit α-galactosidase
A activity and to promote the proliferation of smooth muscle cells [17], likely contributing
to the increased intima-media thickness.
2.2. Pathology
GB3 deposits are found in cardiomyocytes, valve fibroblasts, endothelial and smooth
muscle vascular cells, and cardiac conduction system cells [18–21], representing 1–2% of
the cardiac mass. Nevertheless, in cardiac variants, lysosomal inclusions are only found in
cardiomyocytes [22]. In women, a mosaic pattern of normal and vacuolated cells caused
by random X-chromosome inactivation is observed [23].
GB3 accumulation activates common signaling pathways leading to hypertrophy,
inflammation, apoptosis, necrosis, and fibrosis. Accordingly, anatomopathological analysis
of hearts of FD patients have shown hypertrophy of the cardiomyocytes, myocyte apoptosis
and necrosis, inflammatory infiltrate, replacement and interstitial fibrosis, valve thickening
and vascular intima and media thickening with vascular narrowing [18,21]. Myocardial
disarray may be observed, although it is less pronounced than in sarcomeric HCM [21].
The cardiac involvement by FD is progressive. Progressive cardiomyocyte hyper-
trophy ultimately ends in cell death of enlarged substrate-engorged cardiomyocytes,
either by necrosis or apoptosis, which presumably leads to fibrosis. Accordingly, the
cardiomyocyte diameter, the lysosomal glycosphingolipid area and the extent of necrosis,
apoptosis and fibrosis are all positively correlated with disease severity and age. In the
“pre-hypertrophy” stage, the cardiomyocytes are already mildly hypertrophied and contain
numerous glycosphingolipid-engorged vacuoles, mostly in the perinuclear zone, while the
intramural vessels and interstitium are essentially unaffected, and myocardial fibrosis is not
detectable. In moderate hypertrophy, vacuolar areas occupy > 30% of myocytes, and there
is increased cell apoptosis and necrosis, moderate fibrosis, and thickening and some lumi-
nal narrowing of intramural vessels. In severe hypertrophy, lysosomal inclusions occupy
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~60% of the myocardial cells, and there is extensive myocardial fibrosis and severe narrow-
ing of arteriole lumens. Cell apoptosis seem to prevail in patients with moderate cardiac
hypertrophy, while myocyte necrosis is more pronounced in severe hypertrophy [23].
Endomyocardial biopsies have shown myocarditis in 56% of FD patients. Myocarditis
was detected even before left ventricular hypertrophy (LVH) or late gadolinium enhance-
ment (LGE) and its frequency correlated with disease severity. Myocarditis is immune-
mediated and positive antiheart and antimyosin antibodies were found in all FD patients
with myocarditis [24].
3. Cardiac Manifestations of FD
Cardiac manifestations of FD include ventricular hypertrophy and fibrosis, valve
thickening or regurgitation, heart failure, angina, dysrhythmias, cardiac conduction abnor-
malities, and sudden death [25]. Cardiac signs or symptoms have been reported in 60% of
males and 50% of females, with a mean age of onset of 29.2 ± 14.4 and 34.5 ± 17.6 years,
respectively [26]. Cardiac symptoms were the presenting symptoms of FD in 13% of males
and 10% of females [27] (Table 1). Despite available therapies and supportive treatment,
cardiac involvement carries a major prognostic impact, representing the main cause of
death in FD [26,28].
Table 1. Frequency of cardiac symptoms in FD.
Cardiac Manifestations Frequencies References
Cardiac signs or symptoms
• 60% in males
Mean age of onset 29.2 ± 14.4 years
• 50% in females
Mean age of onset 34.5 ± 17.6 years
• Mehta et al. [26]
Cardiac symptoms as
presenting symptoms
• 13% in males
• 10% in females • Eng et al. [27]
3.1. Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the main cardiac manifestation of FD [25]. FD
has been diagnosed in 0.9% of the patients with HCM [29,30] and, being a treatable disease,
it should be systematically ruled out in all patients with HCM, either by targeted FD
screening or by a wider HCM gene panel including the GLA gene [29]. Basal inferolateral
LGE and bifascicular block were identified as the most powerful predictors of FD in patients
with HCM; therefore, in their presence, a targeted FD screening should be performed,
while in their absence, an HCM gene panel would be the most appropriate next step in the
etiological study of HCM [29].
3.1.1. Left Ventricular Hypertrophy
LVH was found in 43% of males and 26% of females, arising earlier and progressing
more rapidly in males than in females (mean age of onset: 39± 10 vs. 50± 11 years) [31,32].
The prevalence of LVH has been reported to increase with age, occurring in 76.9% of patients
aged ≥ 75 years [33]. Left ventricular (LV) mass index was also found to increase with
age [34,35] and to correlate inversely with estimated glomerular filtration rate (eGFR) [34].
In a late-onset phenotype with predominant cardiac involvement, LVH was detected
in 73.1% of males and 19.0% of females, with a mean age at diagnosis of 57 ± 10 and
73 ± 8 years, respectively. The frequency and severity of LVH also increased with age [4,5].
Although electrocardiographic changes of LVH may predate imaging evidence of LVH
in Fabry patients [35], multimodality cardiac imaging is useful to suggest the diagnosis
of FD, to detect LVH, as well as to monitor the progression of cardiac involvement and
response to therapy [36,37]. Cardiac magnetic resonance imaging (MRI) can detect cardiac
involvement even when the LVH severity is mild, allowing to reclassify 21% of FD patients
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as having cardiac involvement that was previously unrecognized [38]. Of note, recent
studies have suggested that machine learning applied to 3D myocardial architecture and
deformation obtained by cardiac MRI may present increased ability to perform differential
diagnosis of the cause of HCM [39].
LVH secondary to FD is most commonly concentric and symmetric [25,32] (Figure 1);
however, other patterns can also occur, including asymmetric septal hypertrophy, eccentric
hypertrophy, and apical hypertrophy [25,40,41].
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ommended for the earlier detection of LVH in Fabry patients [46], although exclusion of 
papillary muscles seems to be a better predictor of adverse cardiac events (composite end-
point of ventricular tachycardia (VT), bradycardia requiring device implantation, severe 
heart failure, and cardiac death) [47].  
3.1.2. Left Ventricular Storage, Inflammation, and Fibrosis 
Intramyocardial LGE on the basal inferolateral LV segments is typically seen on car-
diac MRI in approximately 50% of Fabry patients [48] (Figure 2), which correlates histo-
logically with focal replacement fibrosis [49]. This LGE pattern was hypothesized to be 
due to increased stress at the interface of the fibrous skeleton of the mitral annulus and 
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ally results in a global subendocardial pattern of LGE [51]. However, this LGE pattern is 
not exclusive of FD and may also be found in myocarditis, Chagas disease, and sarcoidosis 
[52]. 
Figure 1. Left ventricular hypertrophy (LVH) secondary to Fabry disease (FD). Transthoracic echocardiogram of a 70-year-
old male Fabry patient showing a severe symmetrical LVH with prominent papillary muscles in parasternal long-axis (A),
four-chambers (B) and short-axis (C) views.
A binary appearance of the LV endocardial border, known as the “binary sign,”
was correlated with a characteristic pattern of glycosphingolipid compartmentalization
on histological examination and once thought to represent a hallmark feature of Fabry
cardiomyopathy [42]. However, it was later found to be an unreliable marker of Fabry
cardiomyopathy, with an estimated sensitivity of 28.0% and a specificity of 80.0%, occurring
more commonly in patients with LVH and in a more advanced stage of the disease [43].
Prominent papillary muscles are a characteristic feature of FD [25,44] (Figure 1),
while papillary muscles anomalies, such as anterior displacement of the anterolateral
papillary muscles or direct insertion of the papillary muscle into the mitral valve, are very
specific for HCM [45]. Indeed, the papillary muscle contribution to LV mass was found
to be significantly increased in Fabry patients, both with and without LVH, compared
to controls [38]. Hence, the inclusion of papillary muscle mass in LV mass calculation is
recommended for the earlier detection of LVH in Fabry patients [46], although exclusion
of papillary muscles seems to be a better predictor of adverse cardiac events (composite
endpoint of ventricular tachycardia (VT), bradycardia requiring device implantation, severe
heart failure, and cardiac death) [47].
3.1.2. Left Ventricular Storage, Inflammation, and Fibrosis
Intramyocardial LGE on the asal i ferolateral LV segments is typically seen n cardiac
MRI in approximately 50% of Fabry patients [48] (Figure 2), which correlates histologically
with focal replacement fibrosis [49]. This LGE pattern was hypothesized to be due to
increased stress at the interface of the fibrous skeleton of the mitral annulus and the LV
midwall [50]. It allows to differentiate FD from sarcomeric HCM, which usually results in
LGE at the right ventricular (RV) junction points, and amyloidosis, which usually results in
a global subendocardial pattern of LGE [51]. However, this LGE pattern is not exclusive of
FD and may also be found in myocarditis, Chagas disease, and sarcoidosis [52].
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Figure 2. Cardiac magnetic resonance imaging (MRI) (3.0 Tesla) in four Fabry patients, illustrating different stages of
myocardial involvement by the disease. (A) Cine (balanced steady-state free precession sequence) image at the basal left
ventricular (LV) short-axis slice; (B) Late gadolinium enhancement (LGE) at the basal LV short-axis slice; (C) Native T1
mapping (precontrast) performed using a modified Look-Locker inversion (MOLLI) recovery sequence at the basal LV
short-axis slice (the resulting pixel-by-pixel T1 color maps were displayed using a customized lookup table, in which normal
myocardium was green, increasing T1 was yellow and red, and decreasing T1 was blue); and (D) T2 mapping (fast low angle
shot (FLASH)) at basal LV short-axis slice (the resulting pixel-by-pixel T2 color maps were displayed using a customized
lookup table, in which normal myocardium w s purple and increasing T2 was red and yellow). Pat ent 1: A 26-year-old
female without LVH or LGE, presenting normal values of T1 (1265 ± 68 ms at the basal septum) and T2 (41.76 ± 5.40 ms at
the basal septum); Patient 2: A 41-year-old male without LVH or LGE, presenting low T1 (1118 ± 40 ms) and normal T2
(40.93 ± 5.80 ms) values at the basal septum; Patient 3: A 76-year-old female with LVH (LV mass 83 g/m2, maximum wall
thickness 19 mm at the basal septum) and diffuse LGE in the basal segment of the inferolateral wall, who presents low T1
(1093 ± 36 ms) at the basal septum and T1 pseudonormalization particularly at the inferolateral wall (1276 ± 59 ms), where
a mild increase in T2 values (49.10 ± 2.30 ms) was also observed; Patient 4: A 69-year-old male patient with LVH (LV mass
123 g/m2, maximum wall thickness 18 mm at the septum) and diffuse and extensive LGE in the inferolateral wall, who
presents areas of T1 pseudonormalization bu also areas of T1 increase, such as in the inferolateral wall (1425 ± 144 ms),
where T2 values (64.44 ± 8.56 ms) are also incr a ed.
LGE may develop bef re LVH, and a study has reported that 50% of females would
not have been identified with FD cardiomyopathy without the aid of LGE imaging [53].
The preval nce of FD in patients with unexplained LGE has been reported as 2.5% [54].
The “double-peak s gn” n s rain rate by Tissue Doppler I aging (TDI), depicted as
a sharp first p ak in early systole followed by a rapid fall of strain rate approaching zero
and finally a second peak during isovolumetric elaxat on, identifi s segments of LGE with
99% of sensitivi y and 93% of specificity in patients with HCM, aortic stenosis, and FD [55].
Tw - im nsional speckle-tracking can also detect LGE (Figure 3). LV global longitudinal
strain (GLS) is lower in patien s with LGE and reduced long tudi al systolic strain (worse
than −12.5%) in the posterolateral segm nt identifies LGE with 90% of sensitivity and 97%
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of specificity [56]. It was suggested that the absence of ST segment or T wave alterations on
electrocardiogram could almost exclude LGE in FD [57]; however, although LGE has been
significantly associated with ST segment depression and negative T waves, it has been
described in up to 17.8% of the patients without ST depression and 13.4% of the patients
without negative T waves in a large cohort of patients with late-onset FD with predominant
cardiac involvement [5].
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Figure 3. Strain echocardiography for the detection of LGE. (A) Transthoracic echocardiogram
with 2D-strain analysis by speckle tracking showing reduction of longitudinal strain, particularly
in the inferolateral, inferior and inferoseptal walls and apex, in a 73-year-old male Fabry patient;
(B–E) Cardiac MRI (3.0 Tesla) with LGE in short-axis slices, from the LV base to the apex, showing
fibrosis in the same regions where the reduction in longitudinal strain was more pronounced.
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In FD patients with basal inferolateral LGE, troponin levels and T2 values are increased,
suggesting that LGE may also represent inflammation [58] (Figure 2).
LGE was shown to correlate with increased high-sensitivity troponin, and it has been
proposed that normal values of high-sensitivity troponin, in combination with normal
ECG and echocardiogram, indicate that FD cardiomyopathy is unlikely; elevated values of
high-sensitivity troponin indicate advanced FD cardiomyopathy, while borderline values
should lead to a thorough investigation including cardiac MRI. In addition, patients with
increased high-sensitivity troponin presented decreased LV wall thickness and ejection
fraction, suggesting progression of cardiomyopathy [59]. Increased inflammatory markers,
such as interleukin-6 and tumor necrosis factor, were also associated to increased disease
burden (LVH and fibrosis) [60].
In another study, LGE in the basal inferolateral wall was associated to high global
and basal inferolateral wall T2. High basal inferolateral wall T2 was, in turn, associated
with increased troponin and N-terminal prohormone of brain natriuretic peptide (NT-
proBNP), GLS impairment, and electrocardiographic abnormalities (long PR, complete
bundle branch block, LVH voltage criteria, long QTc, and T-wave inversion) and predicted
clinical worsening after 1 year (Fabry stabilization index > 20%) [61].
Finally, LGE regions also showed focal 18F-FDG uptake, further supporting the notion
that LGE represents inflammation [62]. Focal 18F-FDG uptake was also shown before the
development of LGE in FD females, in association to a pseudonormalization of T1 time,
suggesting an intermediate stage of Fabry cardiomyopathy [63]. Focal 18F-FDG uptake was
also shown in 50% of the patients before LVH, being associated with lower LV GLS [64].
LGE at the time of initiation of enzyme replacement therapy (ERT) was associated
to no improvement in LV mass, LV strain, and exercise capacity [65]. Moreover, LGE
was associated with a higher risk of ventricular arrhythmias and sudden cardiac death
(SCD) [66,67] and the annual increase in fibrosis was the only independent predictor of
ventricular arrhythmias [66].
FD has also been associated to low native T1 time on cardiac MRI [68] (Figure 2), which
has been attributed to intracellular glycosphingolipid accumulation [68]. In FD patients
without LVH, low T1 was found in 40% of the cases [68,69] (Figure 2), being associated with
ECG abnormalities and worse LV wall thickness and mass [69,70], LA size [70,71], E/E’
ratio, LV GLS and inferolateral longitudinal strain [71], LV GLS by feature tracking [72],
LGE [69], and worse Mainz Severity Score Index (MSSI) and clinical worsening (Fabry
Stabilization Index > 20%) [70]. In FD with LVH, T1 correlated inversely with LV mass [68].
In patients with LVH, low native T1 time accurately differentiates FD from other causes
of LVH [68], as low T1 times are only otherwise noted in iron overload [73]. Pseudonor-
malization or elevation of T1 in LV inferolateral wall was correlated with the presence of
LGE [68] (Figure 2). In FD patients with RV hypertrophy, low T1 was also found in the
RV [74].
Nordin et al. proposed three stages of cardiac involvement in FD: (1) storage stage with
normal or low native T1 times without LVH; (2) inflammation and myocyte hypertrophy
stage with low native T1 times, inflammation, LGE, chronic troponin elevation, with
LVH in males and without LVH in females; and (3) fibrosis and impairment stage with
pseudonormalization of native T1 times, extensive LGE, LVH, troponin and NT-proBNP
elevation, LV dysfunction, and heart failure [75].
In advanced stages of FD, there is thinning and akinesia of the basal posterior wall,
which may result in asymmetrical LVH [25] (Figure 4) and correlates histologically with
fibrosis [22]. The thinning of the basal posterior wall was found to significantly precede
severe heart failure [New York Heart Association (NYHA) class III] and cardiac death—LV
septum/posterior wall thickness ratio >1.3, 1.5, or 1.7 significantly preceded NYHA class III
heart failure and cardiac death by 4.0, 3.8, or 3.4 and 4.7, 4.5, or 4.1 years, respectively [76].
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Figure 4. Cardiac MRI (3.0 Tesla) in a Fabry patient with advanced cardiomyopathy. Cine (bal-
anced steady-state free precession sequence) images at the basal LV short-axis slice (A) and four-
chamber view (C) showing massive and asymmetrical LVH (maximal thickness 30. mm at the sep-
tum) with thinning of the posterior wall (2 mm). LGE at the basal LV short-axis slice (B) and four-
chamber view (D) showing fibrosis of the inferior and inferolateral walls and apex and focal fibro-
sis in the septum, where the LVH is more pronounced. 
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Figure 4. Cardiac MRI (3.0 Tesla) in a Fabry patient with advanced cardiomyopathy. Cine (balanced
steady-state free precession sequence) images at the basal LV short-axis slice (A) and four-chamber
view (C) showing massive and asymmetrical LVH (maximal thickness 30. mm at the septum) with
thinning of the posterior wall (2 mm). LGE at the basal LV short-axis slice (B) and four-chamber view
(D) showing fibrosis of the inferior and inferolateral walls and apex and focal fibrosis in the septum,
where the LVH is more pronounced.
3.1.3. Left Ventricular Function
Diastolic function is abnormal in 69.4% of those with LVH [4] and 63% of those with
LGE [77]. Diastolic dysfunction occurs more commonly as an abnormal relaxation or a
pseudonormal pattern [25], and it has been associated with the presence of LGE [78] and to
correlate with NT-proBNP [79]. LV systolic dysfunction with reduction in ejection fraction
is rare (6.7%) [80], occurring in late stages of advanced Fabry cardiomyopathy [22,25].
LV systolic and diastolic dysfunction can, however, be detected before the develop-
ment of LVH, not only by TDI [81] but also by speckle-tracking [82,83]. LV longitudinal [82],
circumferential and radial strain [83] were found to be reduced in the pre-hypertrophic
stage; basal segmental longitudinal strain is also impaired even when LV wall thick ess is
normal [84], and the strain rate duri g isovolumic r laxation and the ratio of transmitral
E-wave velocity to the strain rat during isovolumic relaxation have shown to differenti te
FD patients rom controls regardless f LVH [85].
Strain echocardiography has lso s own that mechanical dispersion i higher in FD
patients with LVH than in FD patients without LVH or healthy controls [86]. An apical
sparing patte n on longitudinal strain h s also been described in FD, similarly to amyloi-
dosis [84,87] (Figure 5). Additionally, the loss of the normal base-to- pex circumf rential
strain gradient was suggested to b a specific LV deformation pattern of Fabry cardiom -
opathy, as opposed t non-obstructive HCM that has been associated to a higher global
circumferential strain and a normal base-to- pex gradient [88].
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chamber view (A) and 2 D-strain analysis by speckle tracking revealing an apical sparing pattern 
of GLS (B). 
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of exercise-induced change in stroke volume [91]. 
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free wall systolic strain may be reduced despite normal function on conventional echocar-
diography, and RV systolic dysfunction has been associated to RV wall thickness and fi-
brosis [94]. Although RV hypertrophy and RV systolic function indexes (TAPSE and S’) 
have shown significant association to clinical events, they were not identified as inde-
pendent predictors of their occurrence [95]. 
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Figure 5. Apical sparing pattern of global longitudinal strain (GLS) in a Fabry patient. Transthoracic echocardiogram of a
48-year-old male Fabry patient showing symmetrical LVH in a four-chamber view (A) and 2 D-strain analysis by speckle
tracking revealing an apical sparing pattern of GLS (B).
3.1.4. Left Ventricular
Obstructio t fl tract (LVOT) may occur, but massive LVH involving
the papil ary uscl en reported to cause mid-ventricular obstruction [89].
Obstruction at rest is rare, but it may be licited by exercise in 43% of the patients [90], also
contributing to heart failure. During exercise, FD patients also present lower augmentation
of stroke volume than healthy controls, being E/E’ ratio the independent re ictor of
exercise-induced change in stroke volume [91].
3.1.5. Right Ventricular I l t
RV hypertr cc rs in 31–71% of the patients [92,93]. RV systolic function in
patients with Fabry cardiomyopathy tends to be preserved [93]. Nevertheless, RV global
and free wall systolic strain may be reduced despite normal function on conventional
echocardiography, and RV systolic dysfunction has been associated to RV wall thickness
and fibrosis [94]. Although RV hypertrophy and RV systolic function indexes (TAPSE
and S’) have shown significant association to clinical events, they were not identified as
independent predictors of their occurrence [95].
3.1.6. Atrial Involve ent
Glycolipid deposition in the atria [19] may ultimately cause atrial dilation, which
occurs more commonly in patients with LVH [81] and fibrosis [56]. Left atrial (LA) systolic
and early diastolic strain rate were found preferentially reduced in patients with LVH, but
LA systolic strain was decreased even before LVH [96]. Peak atrial longitudinal strain was
inversely associated to Fazekas score of brain white matter lesions, even after adjusting for
LV mass index [97]. Atrial dilation is associated to the occurrence of atrial fibrillation [98],
which also contributes to heart failure.
3.1.7. Heart Failure
Ventricular hypertrophy and fibrosis result in diastolic and systolic dysfunction, which
together with dysrhythmias and conduction disorders, valve disease, and myocardial
ischemia, contribute to heart failure [25]. Dyspnea or heart failure has been reported in
19.7% of untreated females and 19.4% of untreated males [34]. The prevalence of heart
failure increases with age, occurring in 34.6% of the patients aged ≥ 75 years [33]. In a
late-onset phenotype with predominant cardiac involvement, heart failure was found in
32.9% of males and 14.8% of females and mean survival free from heart failure was 64 ± 1
and 76 ± 2 years, respectively. The frequency of heart failure also increased with age [4,5].
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NT-proBNP levels were correlated to symptom class, LV mass, E/E’ ratio, and LA
size, reaching higher values in patients with LVH, diastolic dysfunction, and LGE [75,99].
Severe heart failure (NYHA class ≥ III) was reported in 10% of FD patients. The
annual incidence of severe heart failure was 1.62 per 100 person-years, and age and MSSI
were independent predictors of its development [100] (Table 2).
Table 2. Frequency of manifestations related to ventricular hypertrophy, fibrosis and dysfunction in FD.
Cardiac Manifestations Frequencies References
LVH
• 43% in males
Mean age of onset 39 ± 10 years
• 26% in females
Mean age of onset 50 ± 11 years
• Mehta et al. [31]
• 76.9% in patients ≥ 75 years • Lidove et al. [33]
In late-onset phenotype with predominant cardiac involvement
• 73.1% of males
Mean age at diagnosis of 57 ± 10 years
• 19.0% of females
Mean age at diagnosis of 73 ± 8 years
• Azevedo et al. [5]
LGE
• 50% of patients • Moon et al. [48]
In late-onset phenotype with predominant cardiac involvement
• 21.4% of patients • Azevedo et al. [5]
LV diastolic dysfunction
• 63% of patients with LGE • Niemann et al. [77]
In late-onset phenotype with predominant cardiac involvement
• 29.2% of patients
• 69.4% of patients with LVH
• Azevedo et al. [4]
LV systolic dysfunction (reduced EF) • 6.7% of patients • Wu et al. [80]
Latent LVOT obstruction • 43% of patients • Calcagnino et al. [90]
RV hypertrophy • 31–71% of patients • Niemann et al. [92]• Graziani et al. [93]
Heart Failure (or Dyspnoea)
• 19.4% in untreated males
• 19.7% in untreated females • Linhart et al. [34]
• 34.6% in patients ≥ 75 years • Lidove et al. [33]
• Severe heart Failure (NYHA class ≥III) in 10%
• Annual incidence of severe heart failure: 1.62 per 100
person-years
• Patel et al. [100]
In late-onset phenotype with predominant cardiac involvement
• 32.9% of males
Mean survival free from heart failure: 64 ± 1 years
• 14.8% of females
Mean survival free from heart failure: 76 ± 2 years
• Azevedo et al. [5]
EF, ejection fraction; LGE, late gadolinium enhancement; LV, left ventricular; LVH, left ventricular hypertrophy; LVOT, left ventricular
outflow tract; NYHA, New York Heart Association; RV, right ventricular.
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3.2. Dysrhythmias and Cardiac Conduction Disorders
As a consequence of dysrhythmias and cardiac conduction disorders, Fabry patients
may experience symptoms, such as palpitations and syncope. Palpitations have been
reported in 15.3% and 21.3% of untreated Fabry male and female patients, while syncope
has been, respectively, reported in 5.6% and 2.4% [34].
3.2.1. Bradycardia, Chronotropic Incompetence, and Cardiac Conduction Disorders
FD involvement of the autonomous nervous system may result in a significantly
reduced heart rate variability in pediatric male patients, reflecting a reduction in parasym-
pathetic stimulation of the heart [101].
GB3 accumulation in the cardiac conduction system cells [20] is constant in men
and variable in women due to X-chromosome inactivation [102]. In an earlier stage, it
may lead to accelerated atrioventricular (AV) conduction, which manifests as a short
PR interval [102,103] (Figure 6). Although there are reports of FD cases with short PR
interval and accessory pathways [104], enhanced AV conduction rather than ventricular
pre-excitation is the most likely cause of the short PR interval. Short PR interval has been
documented in FD patients in whom pre-excitation due to accessory pathways has been
formally excluded [105]. Moreover, a normalization of PR interval has been documented
with ERT [106]. Likewise, in PRKAG2 glycogen-storage cardiomyopathy, the short PR
interval was shown to be directly caused by glycogen storage in and around the AV node,
being reverted by glycogen depletion in the heart [107]. Still, although characteristic, short
PR interval is not common; it has been found in only 14% of FD patients [108].
As FD progresses, GB3 accumulation and fibrosis lead to the development of AV
and bundle-branch blocks [22,109,110] (Figure 6) and sinus node dysfunction [111], which
may require a pacemaker. Bradycardia at rest is common (72%) [112]. Chronotropic
incompetence with exercise due to autonomic nervous dysfunction may also occur and
contribute to heart failure; hence, exercise stress testing or cardiopulmonary exercise testing
could be useful in the differential diagnosis of dyspnea [112,113]. Bradyarrhythmic events
were reported in 23% of the patients and were associated with age, LV mass, ejection
fraction, and LA strain [114]. There was also a positive correlation between LV mass
on cardiac MRI and QRS duration [57]. PR interval duration > 200 ms was reported in
3% and QRS interval duration > 120 ms in 9%. The durations of PR and QRS intervals
were shown to increase with age and were identified as independent predictors of need
of a pacemaker [111]. In a late-onset phenotype with predominant cardiac involvement,
bifascicular block was reported in 25.3% of males and 5.7% of females with a mean age at
diagnosis of 62 ± 6 years in males and 78 ± 6 years in females, and complete AV block was
reported in 12.7% of males and 1.6% of females with a mean age at diagnosis of 60 ± 7 years
in males and 79 ± 6 years in females. The frequency of bundle branch blocks and complete
AV block increased with age as well as the duration of QRS interval [4,5].
3.2.2. Tachydysrhythmias
GB3 deposition in the atria [115] and subsequent fibrosis, together with LVH and dias-
tolic dysfunction and atrial dilation, are the proposed mechanisms of development of atrial
fibrillation [98], which was reported in 3% of FD patients [111]. Another study reported
that 3.9% of the patients had persistent atrial fibrillation and 13.3% had paroxysmal atrial
fibrillation, and age was the only independent predictor of this dysrhythmia [98]. Its annual
incidence was reported as 1 per 100 person-years and age and LV mass were independent
predictors of its development [100]. In a late-onset phenotype with predominant cardiac
involvement, atrial fibrillation was found in 7.6% of males and 2.4% of females, while
atrial flutter in 2.5% and 0.8%, respectively. Mean age at diagnosis of atrial fibrillation was
67 ± 11 years in males and 77 ± 3 years in females [4,5].
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Figure 6. Electrocardiographic findings in FD. (A) Short PR interval in a 34-year-old male, (B) bi-
fascicular and first-degree AV blocks and electrocardiographic criteria of LVH in a 72-year-old 
male, and (C) non-sustained VT in 24 h-Holter monitoring of a 76-year-old male. 
As FD progresses, GB3 accumulation and fibrosis lead to the development of AV and 
bundle-branch blocks [22,109,110] (Figure 6) and sinus node dysfunction [111], which may 
require a pacemaker. Bradycardia at rest is common (72%) [112]. Chronotropic incompe-
tence with exercise due to autonomic nervous dysfunction may also occur and contribute 
Figure 6. Electrocardiographic findings in FD. (A) Short PR interval in a 34-year-old male, (B) bifascicular and first-degree AV
blocks and electrocardiographic criteria of LVH in a 72-year-old male, and (C) non-sustained VT in 24 h-Holter monitoring
of a 76-year-old male.
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A study of 1448 untreated Fabry patients showed ventricular arrhythmias in 13% of
men and 20% of women [116]. In a further study, non-sustained VT was reported in 21%,
while sustained VT in only 1% and bradycardia requiring device in 6% of Fabry patients
during a median follow-up of 3.6 years, suggesting a higher impact of bradyarrhythmic
clinical events [117]. A systematic review of the literature estimated the occurrence of
VT in 15.3% of the patients and reported that 75% of the deaths were due to cardiac
disease and 62% due to SCD, ranging the incidence of SCD events from 0.34% to 1.4%
per annum [67]. In a late-onset phenotype with predominant cardiac involvement, non-
sustained VT (Figure 6) was found in 14.1% of males and 5.6% of females, with a mean age
at diagnosis of 57 ± 8 and 70 ± 6 years, respectively [4,5].
GB3 accumulation in cardiac conduction system has been reported in FD patients
presenting with VT in the absence of LVH, suggesting that GB3 deposits may precipitate
VT [118]. However, the major mechanism of sustained VT in FD appears to be re-entry
related to myocardial fibrosis [119].
Indeed, the annual increase in fibrosis during follow-up was identified in a study as
the only independent predictor of malignant ventricular arrhythmias [66]. Other study
showed that SCD only occurred in patients with documented VT and LGE [120]. Patients
with elevated LV mass index also had more overall arrhythmia, ventricular arrhythmia,
and sustained VT [50]. Finally, a systematic review of the literature identified age, male
gender, LVH, LGE, and non-sustained VT as risk factors associated with SCD events [67].
Sympathetic nerve damage, demonstrated by MIBG defects in the inferolateral wall,
occurs in FD patients without LGE and, in patients with LGE, MIBG defects are larger
than the LGE areas, suggesting that sympathetic nerve damage precedes myocardial
fibrosis [121]. Therefore, MIBG may have a unique role in assessing the risk of ventricular
arrhythmia and SCD [36].
Dysrhythmias occur especially in late stages of the disease [22]. Implantable loop
recorders (ILR) revealed clinically relevant dysrhythmias, including four episodes of asys-
tole, seven of bradycardia, five of paroxysmal atrial fibrillation, and five of VT (three
sustained and two non-sustained) in 16 patients with advanced cardiomyopathy, with no
abnormalities on Holter, followed for a median of 1.2 years. These findings led to new
management decisions (pacemaker or ICD implantation, anticoagulation, and termination
of beta-blockers) in more than half of them (n = 9) [122].
3.2.3. Cardiac Devices
In a study, the annual rate of cardiac device implantation was estimated at 1.90 per
100 person-years. A pacemaker was needed in 12.5% of the patients due to AV blocks or
sinus node dysfunction, and an implantable cardioverter-defibrillator (ICD) was placed in
4.2% due to non-sustained VT. Age at diagnosis of FD and age at the last follow-up visit
were independently associated with an increased risk of rhythm/conduction abnormalities
requiring cardiac device [123]. The annual incidence of cardiac device implantation for
the treatment of bradycardia was 1.07 per 100 person-years and age and QRS duration
were independent predictors of device implantation [100]. Another study reported a 5-year
cumulative incidence of pacemaker implantation of 8%, which is more than 25 times greater
than in general population [111]. In a late-onset phenotype with a predominant cardiac
involvement, a pacemaker was implanted in 12.7% of males and 2.4% of females and an
ICD in 1.3% and 0.8%, respectively. Mean survival free from pacemaker was 71 ± 2 and
86 ± 1 years, respectively [4,5] (Table 3).
Patients with devices were older, had greater LV mass, more scar tissue and larger
atrial size. A class I indication for device implantation was found in 92% of the patients
with permanent pacemakers, but in only 28% of the patients with ICD. Moreover, further
44% of patients had ICD inserted for primary prevention outside of current guidance [124].
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Table 3. Frequency of dysrhythmias and cardiac conduction disorders in FD.
Cardiac Manifestations Frequencies References
Palpitations • 15.3% in untreated males• 21.3% in untreated females • Linhart et al. [34]
Syncope • 5.6% in untreated males• 2.4% in untreated females • Linhart et al. [34]
Short PR interval • 14% of patients • Namdar et al. [108]
Bradycardia • 72% of patients • Lobo et al. [112]
Bradyarrhythmic events • 23% of patients • Di et al. [114]
PR interval > 200 ms • 3% of patients • O’Mahony et al. [111]
QRS duration > 120 ms • 9% of patients • O’Mahony et al. [111]
Right bundle branch block
In late-onset phenotype with predominant cardiac involvement
• 38.8% of males
Mean age at diagnosis of 61 ± 6 years
• 8.5% of females
Mean age at diagnosis of 76 ± 9 years
• Azevedo et al. [5]
Left anterior fascicular block
In late-onset phenotype with predominant cardiac involvement
• 45.5% of males
Mean age at diagnosis of 60 ± 7 years
• 10.3% of females
Mean age at diagnosis of 72 ± 14 years
• Azevedo et al. [5]
Bifascicular block
In late-onset phenotype with predominant cardiac involvement
• 25.3% of males
Mean age at diagnosis of 62 ± 6 years
• 5.7% of females
Mean age at diagnosis of 78 ± 6 years
• Azevedo et al. [5]
Complete AV block
In late-onset phenotype with predominant cardiac involvement
• 12.7% of males
Mean age at diagnosis of 60 ± 7 years
• 1.6% of females
Mean age at diagnosis of 79 ± 6 years
• Azevedo et al. [5]
Atrial Fibrillation
• 3% of patients • O’Mahony et al. [111]
• 3.9% of patients had persistent atrial fibrillation
• 13.3% of patients had paroxysmal atrial fibrillation • Shah et al. [98]
• Annual incidence: 1 per 100 person-years • Patel et al. [100]
In late-onset phenotype with predominant cardiac involvement
• 7.6% of males
Mean age at diagnosis of 67 ± 11 years
• 2.4% of females
Mean age at diagnosis of 77 ± 3 years
• Azevedo et al. [5]
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Table 3. Cont.
Cardiac Manifestations Frequencies References
Atrial Flutter
In late-onset phenotype with predominant cardiac involvement
• 2.5% of males
• 0.8% of females
• Azevedo et al. [5]
Ventricular Arrhythmias
• 13% in males
• 20% in females • Pinderski et al. [116]
• Non-sustained VT in 8.3% of patients during 1.9 years of follow-up
(n = 78) • Shah et al. [98]
• Non-sustained VT in 21% of patients
• Sustained VT in 1% of patients
(Median follow-up of 36 months)
• Hanneman et al. [117]
Systematic review of the literature
• VT in 15.3% of the patients • Baig et al. [67]
In late-onset phenotype with predominant cardiac involvement
• Non-sustained VT in 14.1% of males
Mean age at diagnosis of 57 ± 8 years
• Non-sustained VT in 5.6% of females
Mean age at diagnosis of 70 ± 6 years
• Azevedo et al. [5]
SCD
• SCD in 1 patient during 1.9 years of follow-up (n = 78) • Shah et al. [98]
• VF in 1 patient in the setting of multiorgan failure during mean
follow-up of 53 months (n = 19) • Acharya et al. [125]
Systematic review of the literature
• 62% of cardiac deaths are sudden
• Incidence of SCD events: 0.34–1.4% per annum
• Baig et al. [67]
Cardiac device
• Annual incidence: 1.9 per person-years • Sené et al. [123]
• Annual incidence of devices for the treatment of bradycardia (pace-
maker/ICD): 1.07 per person-years • Patel et al. [100]
Pacemaker
• 12.5% of patients • Sené et al. [123]
• 5-year incidence: 8% • O’Mahony [111]
In late-onset phenotype with predominant cardiac involvement
• 12.7% in males
Mean survival free from pacemaker: 71 ± 2
• 2.4% in females
Mean survival free from pacemaker: 86 ± 1
• Azevedo et al. [5]
ICD
• 4.2% of patients • Sené et al. [123]
In late-onset phenotype with predominant cardiac involvement
• 1.3% in males
• 0.8% in females
• Azevedo et al. [5]
AV, atrioventricular; ICD, implantable cardioverter-defibrillator; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular
tachycardia.
3.3. Coronary Manifestations
GB3 accumulation results in hypertrophy and proliferation of smooth muscle and
endothelial cells and widespread narrowing of intramural coronary arteries [21,126].
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On angiography, epicardial coronary arteries have been described as structurally
normal, but presenting slow flow, and small vessel disease correlated with coronary slow
flow and extent of fibrosis [126].
Hence, FD patients with angina present myocardial ischemia on exercise stress test,
myocardial perfusion defects on single-photon emission computed tomography [126],
and reduced myocardial blood flow and coronary flow reserve on positron emission
tomography (PET) [127–129]. Myocardial blood flow is reduced in patients without LVH,
both males and females, although it is more reduced in patients with LVH [129]. Perfusion
defects showed marked regional heterogeneity, with prevalent hypoperfusion of the apical
region [129]. In cardiac MRI including vasodilator stress perfusion mapping, the stress
myocardial blood flow is also lower in all FD patients regardless of LVH status, although
the reduction is more pronounced in patients with LVH. The reduction in stress myocardial
blood flow is more pronounced in the subendocardium than in the subepicardium. LGE
and low T1 were identified as independent predictors of stress global myocardial blood flow,
while LV wall thickness, LGE, and T2 value as predictors of stress segmental myocardial
blood flow [130].
Besides coronary microvascular dysfunction, coronary vasospasm may also contribute
to angina [131,132] and may precipitate dysrhythmias and sudden death [133].
Oxygen supply to myocardium may also be impaired by LVOT obstruction and in-
creased LV diastolic filling pressure, which reduce blood perfusion of the subendocardial
layer of myocardium. Taken together with an increased demand of oxygen by the hyper-
trophied myocardium, the result is myocardial ischemia, which may be asymptomatic
or manifest as angina and myocardial infarct or contribute to dysrhythmias and heart
failure [134,135].
Moreover, FD patients commonly present cardiovascular risk factors and may develop
coronary atherosclerotic disease. It is not clear if FD may increase the risk of accelerated
atherosclerosis [136].
Angina has been reported in 22% of males and 23% of females with FD [134]. Mean age
of onset was reported to be 42± 5 and 49± 13 years in males and females, respectively [31].
It may be the first manifestation of FD cardiomyopathy, preceding the development of
LVH [137]. However, myocardial infarct is rare (<2%) [134], occurring in 2.7% of males and
1.5% of females [138] (Table 4). Hence, FD remains a rare cause of chest pain in patients
without obstructive coronary artery disease (0.15%) [139].
3.4. Valvular Disease
GB3 accumulation in valve fibroblasts may ultimately lead to valve thickening and
fibrosis [18,19] and regurgitation [20,35], which are usually mild/moderate and rarely
require intervention [25,35]. Left-sided valves are most affected, probably due to greater
hemodynamic stress [134]. Aortic valve was reported to be affected in 47% of the cases
and mitral valve in 57% [35] (Table 4). Mitral valve prolapse has also been described [140],
although now known to be less prevalent than originally reported [35]. Aortic root dilation
may also occur in late stages of the disease, thereby contributing to aortic regurgitation [35].
The development of valve dysfunction also contributes to heart failure [25].
3.5. Aortic Dilation
Degenerative changes in the aortic media from glycolipid deposition [19] can lead
to aortic dilatation at the sinuses of Valsalva and ascending aorta in 32.7% and 29.6% of
males and 5.6% and 21.1% of females, respectively [141]. An aortic aneurysm, defined as
an aortic diameter exceeding 1.5 times the upper limit of normal at the sinuses of Valsalva,
was found in 9.6% of male and 1.9% of female patients [141] (Table 4).
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Table 4. Frequency of other cardiac manifestations in FD.
Cardiac Manifestations Frequencies References
Angina
• 22% in males
• 23% in females • Linhart et al. [134]
• Mean age of onset in males: 42 ± 5years
• Mean age of onset in females: 49 ± 13 years • Mehta et al. [31]
Myocardial infarct
• <2% • Linhart et al. [134]
• 2.7% in males
• 1.5% in females • Patel et al. [138]
Aortic valve dysfunction • 47% of patients • Linhart et al. [35]
Mitral valve dysfunction • 57% of patients • Linhart et al. [35]
Aortic dilation
At the sinuses of Valsalva
• 32.7% in males
• 5.6% in females
At the ascending aorta
• 29.6% in males
• 21.1% in females
• Barbey et al. [141]
Aortic aneurysm • 9.6% in males• 1.9% in females • Barbey et al. [141]
3.6. Cardiac Events
The incidence of adverse cardiac events (composite endpoint of VT, bradycardia
requiring device implantation, severe heart failure, or cardiac death) was 7.6% per year;
LVH and LGE were predictors of adverse cardiac events and patients with extensive LGE
(≥15% of LV mass) were at highest risk [117]. In another study, the incidence of the primary
endpoint (a composite of new onset atrial fibrillation, NYHA ≥ III symptoms, device
insertion for bradycardia, or cardiac death) was 2.64 per 100 person-years. Age, MSSI, and
QRS duration were independent predictors of the primary endpoint [100]. Age, eGFR,
high-sensitivity troponin I, NT-proBNP, LV mass index, E/E’ ratio, and GLS have shown
incremental value in the prediction of adverse cardiac events (defined as composite of
cardiac death, malignant VT, atrial fibrillation, or severe heart failure) [142] (Table 5).
Cardiac events (defined as myocardial infarction, arrhythmia, angina pectoris, conges-
tive heart failure, or significant cardiac procedures, such as pacemaker placement, coronary
bypass, stent placement, and valve replacement) were reported in 69.9% of males and
81.6% of females. Cardiac events were the first clinical events in 21.4% of males and 16.9%
of females. Age at first cardiac event was 41.7 (5.3–80.4) in males and 49.8 (17.3–78.2) in
females [28].
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Table 5. Predictors/Factors associated to cardiac events in FD.
Cardiac Endpoints Predictors/Factors Associated to Outcome References
Composite endpoint of VT, bradycardia requiring device




Extensive LGE (≥15% of LV mass) were at
highest risk
• Hanneman et al. [117]
Composite endpoint of new onset atrial fibrillation, NYHA ≥





• Patel et al. [100]
Composite endpoint of myocardial infarction, heart failure, or
cardiac-related death
Predictor
• LVH • Patel et al. [138]
Composite endpoint of death, myocardial infarction, cerebral
vascular accident, exacerbation of heart failure, arrythmia, or
implantation of permanent pacemaker or
cardioverter-defibrillator
Associated factor
• Impaired basal segmental longitudinal
strain
• Zada et al. [84]
Composite endpoint of sudden death, arrhythmia or pacing
device insertion
Predictor
• End-stage renal disease • Talbot et al. [143]





• High-sensitivity troponin I
• NT-proBNP
• LV mass index
• E/E’ ratio
• GLS
• Spinelli et al. [142]
eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; LGE, late gadolinium enhancement; LV, left ventricular; LVH,
left ventricular hypertrophy; MSSI, Mainz severity score index; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA,
New York Heart Association; VT, ventricular tachycardia.
Ultimately, heart disease is the main cause of death of Fabry patients (40% in males
and 41.7% in females) [28]. Cardiac death occurred in 3.4% over a mean follow-up period
of 7.1 years (2.4% due to SCD and 1.0% due to heart failure). The annual incidence of
cardiac death was 0.52 per 100 person years and the only independent predictor was LV
mass [100]. Cardiac death was reported to occur at a median age of 55.5 years in males and
66.0 years in females [28]. All-cause mortality and heart failure-related mortality is higher
in patients with FD than with sarcomeric HCM [144].
Table 6 summarizes the main recommendations for the diagnosis and monitoring of
cardiac manifestations in FD.
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Table 6. Summary of the main recommendations for the diagnosis and monitoring of cardiac
manifestations in FD [145].
Recommendations for the Diagnosis and Monitoring of Cardiac Manifestations in FD
ECG
A standard 12-lead ECG is recommended in all adult patients at first clinical evaluation, every 6–12 months
and when there is development of new symptoms.
Echocardiogram
Echocardiogram is recommended in all patients at baseline, every 12–24 months and with the development of
new symptoms.
Exercise echocardiography
Exercise echocardiography should be performed in all symptomatic patients to exclude latent obstruction and
exercise-induced mitral regurgitation.
Cardiac MRI
Cardiac MRI should be considered in all adult patients at baseline to assess cardiac morphology and function
and myocardial fibrosis; and may be considered, every 2–5 years in patients without cardiac abnormalities
and every 2–3 years in patients with progressive disease, in order to assess progression of fibrosis and
cardiac function.
T1 mapping may also be considered to detect early cardiac involvement or to help in the differential diagnosis
of LVH.
Holter monitoring
A 24 h-Holter monitoring should be considered in all adult patients at first clinical evaluation, every 6–12
months and when there is development of new symptoms.
ILR
A prolonged Holter monitoring or preferably an ILR should be considered in patients with recurrent episodes
of unexplained syncope.
An ILR may also be considered in patients with palpitations or recent stroke and negative Holter monitoring.
Cardiopulmonary exercise testing
Cardiopulmonary exercise testing should be considered in patients with exercise intolerance.
Coronary angiography
Coronary angiography (or CT coronary angiography) is recommended in all patients with angina CCS class ≥ II.
Invasive coronary angiography is recommended in adult survivors of cardiac arrest, in patients with
sustained VT and in patients with severe stable angina (CCS class III) or unstable angina.
BNP/NT-proBNP
Measurement of plasma BNP/NT-proBNP is recommended in symptomatic patients with suspected
heart failure.
High-sensitivity troponin
High-sensitivity troponin may be considered to assess disease severity.
Renal function
Regular assessment of renal function and albuminuria/proteinuria is recommended in all patients.
Endomyocardial biopsy
When a genetic variant of uncertain significance is found in the GLA gene, an endomyocardial biopsy with
electron microscopy should be considered, particularly in females or in patients with high residual enzyme
activity (>10%) and low lyso-GB3 levels, in order to exclude FD as the cause of LVH.
BNP, brain natriuretic peptide; CCS, Canadian Cardiovascular Society; CT, computed tomography; ECG, electro-
cardiogram; FD, Fabry disease; ILR, implantable loop recorder; LVH, left ventricular hypertrophy; MRI, magnetic
resonance imaging; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; VT, ventricular tachycardia.
4. Late-Onset Phenotypes with Predominant Cardiac Involvement (“Cardiac Variants”)
Cardiac involvement may be the predominant feature in some late-onset phenotypes.
These phenotypes, commonly designated by some authors as “cardiac variants” of FD, have
been described in association to the GLA mutations p.F113L [4,5,146], p.N215S [147–150],
IVS4+919G>A [151], p.A20P [152], p.I91T [146], p.N139S [153], p.I232T [154], p.I239M [155],
p.Q279E [156,157], p.M296I [152,158], p.M296V [159], p.R301Q [156,157,160], and p.G328R [161].
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Some of these mutations are very common and, despite their widespread distribution
around the world, they occur in large clusters in specific geographical areas, such as the
IVS4+919G>A mutation in Taiwan, the p.N215S mutation in the United Kingdom, and the
p.F113L mutation in the Portuguese region of Guimarães. Indeed, a founder effect has
already been documented for the IVS4+919G>A mutation in Southern China [162] and the
p.F113L mutation in the Portuguese region of Guimarães [4,29].
These GLA mutations are associated to residual enzymatic activity of α-galactosidase
A [4,5,150,163]. Plasma lyso-GB3 levels are lower than in patients with classic phenotypes in both
genders, and normal or near-normal values are usually found in these females [4,5,150,164–169].
Cardiac deposits of GB3 are only found in myocardial cells [22,164,167,170,171].
Cardiac manifestations are common and carry the highest prognostic impact [4,5].
Despite the attenuated course of late-onset phenotypes, the severity of cardiac involvement
is the same or greater than in classic phenotypes [164,172]. LVH remains the most common
cardiac manifestation, occurring in 40.2% of the patients (21–67%) [5]. The first cardiac
manifestations are LVH and LGE, which arise in males over 30 years and are followed by
heart failure, non-sustained VT, and cardiac conduction disorders, which arise in males
over 40 years, culminating with the development of bifascicular block and complete AV
block in males beyond the age of 50 years. Cardiac manifestations are more common and
arise one to two decades earlier in males, and their frequency and severity increase with
age in both genders [5].
In these late-onset phenotypes, acroparesthesias, neuropathic pain, hypohidrosis, heat,
cold and exercise intolerance, gastrointestinal symptoms, angiokeratomas, and cornea verticil-
lata are characteristically absent or rare [4,5,150,163,165,166,169,172]. However, other extracar-
diac manifestations, such as proteinuria, brain white matter lesions, and deafness, are common
and arise early, before 30 years of age. Their prognostic impact, however, is lower, as renal in-
sufficiency, stroke, and need for a hearing device is uncommon [4,5,150,165,166,169,172–174].
5. Cardiac Treatment in FD
5.1. ERT
ERT with recombinant α-galactosidase A has been approved for clinical use since
2001. There are two commercially available preparations, agalsidase alfa and agalsidase
beta, both administered intravenously every other week at the doses of 0.2 and 1 mg/kg of
body weight, respectively [175].
According to the current recommendations, ERT should be initiated in classic males
at the age of 16 years regardless of symptomatic status, although it should be consid-
ered earlier, on an individual basis, since the age of 8–10 years old. In late-onset males
and in classic/late-onset females, LVH, cardiac fibrosis or cardiac rhythm, or conduction
abnormalities constitute indications to start ERT [176].
Agalsidase alfa has been demonstrated to decrease/stabilize LV mass [177–179] and
wall thickness [179] in males, as well as to decrease/stabilize LV mass [178–181] and wall
thickness [179] and to improve exercise capacity [181] in females. However, myocardial
GB3 content did not significantly decrease on endomyocardial biopsies taken at 6 months of
treatment with agalsidase alfa [177]. In a study comparing patients treated with agalsidase
alfa from the Fabry Outcome Survey registry with historical cohorts of untreated patients,
the median age at first event seemed to be higher in patients under agalsidase alfa than
in untreated patients, both in males (48 vs. 41 years) and females (57 vs. 53 years). The
median survival time also seemed to be higher in males under agalsidase alfa than in
untreated males (77.5 vs. 60 years). However, these findings have to be interpreted with
caution because this study was a retrospective analysis that used a historical cohort as a
comparator group [182].
Agalsidase beta has been shown to reduce/stabilize LV mass [128,183–185] and wall
thickness [128,185] in males, as well as to decrease/stabilize LV mass [183,185] and wall
thickness [185] in females. Complete clearance of GB3 deposits was also achieved in inter-
stitial capillary endothelial cells from 72% of the patients treated with agalsidase beta for
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5 months, and this benefit seemed to be sustained up to 60 months. Nevertheless, no clear-
ance of GB3 was observed in the cardiomyocytes [186]. Conversely, in another study, there
was no improvement of GB3 deposits in endothelial and smooth muscle cells, myocardial
blood flow, perfusion defects, or electrocardiographic changes on exercise stress test with
agalsidase beta for ≥12 months [126]. In a randomized clinical trial, agalsidase beta, com-
pared to placebo, significantly increased the time to first clinical event in protocol-adherent
patients, when adjusted for baseline proteinuria (considering clinical events as cardiac:
myocardial infarction; new symptomatic arrhythmia requiring antiarrhythmic medication,
pacemaker, direct current cardioversion, or defibrillator implantation; unstable angina
defined by national practice guidelines and accompanied by electrocardiographic changes
resulting in hospitalization; or worsening congestive heart failure requiring hospitaliza-
tion; renal: 33% increase in serum creatinine level from baseline (2 consecutive values) or
end-stage kidney disease requiring long-term dialysis or transplantation; cerebrovascular:
stroke or transient ischemic attack; or death). However, most clinical events were renal
and these were limited to the increase in serum creatinine, while there was a low rate
of cerebrovascular events and death [187]. Moreover, agalsidase beta has reduced the
incidence rate of clinicals events after 6 months of treatment, maintaining, from 6 months
to up to 5 years of treatment, a stable incidence rate of clinical events (cardiac: myocardial
infarction, first-time congestive heart failure, atrial fibrillation, VT, evidence of progressive
heart disease sufficiently severe to require a pacemaker, heart bypass surgery, coronary
artery dilatation or implantation of an ICD; renal: chronic dialysis (>40 days) or renal
transplantation; cerebrovascular: hemorrhagic or ischemic stroke; or death due to any
cause) [188].
The evaluation of ERT efficacy in the late-onset phenotypes with predominant cardiac
involvement has been limited to a few small studies in the IVS4+919G>A mutation. In
these patients, a significant negative correlation has been described between ERT duration
and GB3 accumulation in cardiomyocytes and cardiomyocyte size [189]. In patients under
ERT for more than 3 years, GB3 deposits were not found in cardiomyocytes [170]. In a
study including 23 patients with the IVS4+919G>A mutation, plasma lyso-Gb3 decreased
under ERT both in males and females, reaching the lowest value at 11.1 months and in-
creasing gradually thereafter, even when LV mass index was still improving or remaining
stable [167]. Finally, in another study, including 26 patients with the IVS4+919G>A mu-
tation under ERT for 6–39 months, a significant reduction in mean plasma lyso-GB3 (on
average by 28%) has been reported in males and females, with 89% of patients experi-
encing a reduction in plasma lysoGB3. A stabilization or reduction in LV mass index,
interventricular septum and posterior wall thickness has been observed in 83%, 83%, and
67% of patients, respectively, with an average decrease in 12% in LV mass index, 14%
in interventricular septum, and 13% in posterior wall thickness. Mean LV mass index,
interventricular septum, and posterior wall thickness have been found to decrease both in
males and females, although only reaching statistical significance for LV mass index and
posterior wall thickness in females [166].
Better cardiac outcomes are achieved with early treatment. Agalsidase beta was
associated to a statistically significant decline in LV mass when started at the age < 30 years,
but an increase in LV mass was seen when it was started at the age ≥ 50 years [184].
Likewise, agalsidase beta started at the age < 40 years was associated to a stable thickness
of the interventricular septum and posterior wall over a period of 10 years, whereas a
significant worsening of these parameters was observed over time when it was started at
the age ≥ 40 years [190]. Moreover, in patients without fibrosis, agalsidase beta resulted
in a statistically significant decline of LV mass and improvement of exercise capacity and
LV radial strain rate, while no effect was observed in patients with mild or severe fibrosis
at the time of treatment initiation [65]. Similarly, in patients treated with agalsidase alfa,
LVH or low eGFR at the time of treatment initiation were associated with a higher risk of
cardiovascular events [191].
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A study comparing agalsidase alfa and agalsidase beta found that a higher proportion
of patients had a decrease in LV mass index when treated for 1 year with agalsidase beta
than with agalsidase alfa at licensed doses (79% vs. 62%). Nevertheless, no difference
between agalsidase alfa and beta was found regarding clinical events [192].
Neutralizing anti-drug antibodies may attenuate ERT efficacy. Although previous
reports have suggested that anti-drug antibodies had no effect on the time to first clinical
event [193], other studies have shown that they were associated to higher LV mass, disease
severity scores, and frequency of symptoms [194] and worse renal function [194,195].
5.2. Migalastat
Migalastat is a first-in-class pharmacological chaperone therapy for FD, administered
orally at the dosage of 123 mg once every other day, which has been approved by the
European Medicines Agency for the treatment of FD patients aged ≥ 16 years, with eGFR
≥ 30 mL/min/1.73 m2 and amenable GLA mutations [175,196].
Migalastat has consistently shown to decrease LV mass [197–203]. In the FACETS
trial, in the modified-intention to treat population (i.e., ERT-naïve patients with migalastat-
amenable GLA mutations), there was a significant reduction in the mean LV mass index
compared to the baseline after 24 months of migalastat therapy (i.e., after 18 months
of migalastat in patients who switched from placebo or 24 months of continuous mi-
galastat) [197]. In the ATTRACT trial, in ERT-experienced patients with amenable GLA
mutations who were randomized to switch to migalastat or continue ERT, migalastat
significantly reduced the mean LV mass index at 18 months, and changes on LV mass
index correlated with changes in the thickness of the interventricular septum and not the
posterior wall [198]. In the open-label extension study, a significant decrease in LV mass
index was found after 30 months of migalastat in patients with LVH at baseline [199].
Muntze et al. reported one patient who showed improvement of LV mass, LGE, troponin,
and NT-proBNP under treatment with migalastat for 12 months [200]. Later, the same
authors reported a decrease in LV mass index in 14 patients treated with migalastat for
1 year [201]. Riccio et al. also reported a significant decrease in LV mass index after 1 year
of treatment with migalastat in seven FD males previously treated with ERT [202]. In the
larger FAMOUS study, including 59 previously ERT-treated and untreated FD patients,
treatment with migalastat for 12 months was also associated to a significant decrease in LV
mass index [203].
No data have been published on the efficacy of migalastat specifically on the late-
onset phenotypes.
5.3. Supportive Treatment
Control of cardiovascular risk factors, including arterial hypertension and dyslipi-
daemia is indicated [134]. Systolic blood pressure was higher in patients with LGE and
highest in patients with a faster progression of LGE [204]. In fact, hypertension increased
the odds of cardiovascular events (myocardial infarction, heart failure, or cardiac-related
death) by 7.8 in men and 4.5 in women [138].
Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers should
be used in patients with LVH, LV systolic dysfunction, and heart failure, but also in the
presence of proteinuria [25,51,145,205,206]. Mineralocorticoid receptor antagonists should
also be considered in patients with heart failure and LV systolic dysfunction [51,145].
However, these drugs must be used with caution in patients with nephropathy due to the
possible development of hyperkalemia or worsening of renal function [145]. Evidence is
lacking on the use of sacubitril/valsartan in Fabry patients.
Beta-blockers are recommended to relieve LVOT obstruction symptoms or control the
rate of atrial fibrillation/flutter and should be considered in patients with angina or heart
failure and LV systolic dysfunction [25,51,145,207,208]. Verapamil should also be consid-
ered for the treatment of angina and is recommended for the treatment of LVOT obstruction
symptoms. Diltiazem should also be considered in patients with LVOT obstruction symp-
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toms or angina. Ivabradine should be considered for the treatment of heart failure or
angina, according to the European Society of Cardiology (ESC) guidelines [51,145,207,208].
However, these drugs must be handled with care, due to the propensity of FD patients
to develop chronotropic incompetence and bradydysrhythmias. Dihydropyridine cal-
cium channel blockers may be safer alternatives and should be considered for angina
treatment [134,208].
Loop diuretics should be considered to treat symptoms of congestion in patients with
heart failure [134,207].
Cardiac resynchronization therapy (CRT) has also been applied in a few FD cases at
burn-out stage with LV systolic dysfunction and heart failure [209], but its efficacy in this
cohort of patients may be hampered by extensive scar burden. Nevertheless, it should
be considered in patients with LV dysfunction (ejection fraction ≤ 35%), according to the
current ESC guidelines [207]. CRT-P should also be considered in symptomatic patients
with a pacing indication, LV ejection fraction < 50%, and QRS duration > 120 ms [145].
In patients with resting or latent LVOT obstruction, digoxin is not recommended and
vasodilators, such as angiotensin converting enzyme inhibitors, angiotensin II receptor
blockers, dihydropyridines, and nitrates, should be avoided, if possible [51,145]. Myec-
tomy should be performed in the rare cases of LVOT obstruction associated with severe
symptoms of heart failure or syncope, resulting in excellent operative outcome and relief
of LVOT obstruction and symptoms [210]. Septal alcohol ablation may be a safe alternative
treatment for alleviation of LVOT obstruction and improvement of related heart failure in
Fabry patients [211].
Antiplatelet aggregation therapy should be started in patients who suffered a stroke
or myocardial infarction [134]. Anticoagulation should be immediately started once atrial
fibrillation or flutter is detected [134], based on the evidence extrapolated from HCM, and
no risk score should be used for this purpose as none has been validated in FD [145]. Direct
oral anticoagulants (DOACs) should be considered as the first-line choice in Fabry patients
without contraindications, namely, related to renal failure, because, despite the lack of
systematic data on their use on FD, they are associated to lower risk of intracranial bleeding
and may avoid the risk of warfarin-induced nephropathy [145].
Prior stroke/transient ischemic attack (TIA), angiokeratoma, LV posterior wall thick-
ness >14 mm, creatinine ≥1.0 mg/dL, and GLS > −13.5% were identified as independent
risk factors for new or recurrent stroke/TIA in FD patients without atrial fibrillation. A
new predicting score based on these risk factors was proposed to predict stroke/TIA in FD
patients without atrial fibrillation. It remains to clarify if high-risk patients, according to
this score, might benefit from antithrombotic therapy [212].
Amiodarone should be avoided in FD patients, as it induces lysosomal dysfunction
and may precipitate clinical worsening [213]. It induces phospholipidosis by inhibiting lyso-
somal degradation of phospholipids [214]. Additionally, dronedarone is contraindicated
in patients with heart failure (NYHA class III–IV) and renal failure (eGFR < 30 mL/min).
Sotalol, flecainide, and propafenone are also contraindicated in patients with heart fail-
ure [145].
Isolation of pulmonary veins has been performed [215], but it may require longer and
repeated procedures [216].
Pacemaker may be required to treat symptomatic bradycardia or symptomatic/advanced
cardiac blocks, according to ESC guidelines [134,145].
ICD implantation is recommended in patients who suffered sudden cardiac arrest
due to VT/ventricular fibrillation or sustained VT causing syncope or hemodynamic
compromise and have a life expectancy of >1 year [145]. ICD implantation should be
considered in patients with advanced hypertrophy and fibrosis, who require pacemaker
implantation and have a life expectancy of >1 year [145]. Evidence is lacking to guide ICD
implantation in primary prevention in FD patients and the HCM RISK-SCD score should
not be used for this purpose [145]. Nevertheless, it is generally accepted that FD patients
should receive ICD in the presence of heart failure (NYHA class II–III) and LV ejection
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fraction of ≤35% [207]. Patients who have significant fibrosis on MRI and those who have
non-sustained VT on Holter monitoring are at higher risk for arrhythmic complications and
may be considered for ICD [66,123,145]. VT ablation has also been performed with success
in some cases of recurrent VT or ICD storms [119]. However, radiofrequency ablation by
endocardial and/or epicardial approaches is challenging, as the target tissue is frequently
localized at the midwall [216]. Asymptomatic runs of non-sustained VT do not usually
require anti-arrhythmic therapy [145].
Heart transplantation should be considered in patients with advanced heart failure
with severe LV systolic and diastolic dysfunction and NYHA class III–IV despite optimal
medical therapy, or intractable ventricular arrhythmia, depending on the extension of the
extracardiac involvement by the disease and considering that the disease does not affect
the transplanted organ [134,217] (Table 7).
Table 7. Summary of the main recommendations for the supportive treatment of cardiac manifesta-
tions in FD.
Recommendations for the Supportive Treatment of Cardiac Manifestations in FD
Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers 1,2
Angiotensin converting enzyme inhibitors (or angiotensin II receptor blockers, if not tolerated) should be used
in patients with LV systolic dysfunction and heart failure [25,51,145].
Beta-blockers 3
Beta-blockers should be considered in patients with heart failure and LV systolic dysfunction; or in patients
with angina [25,51,145,207,208].
Beta-blockers are recommended to relieve LVOT obstruction symptoms and to control the rate of atrial
fibrillation/flutter [25,51,145].
Mineralocorticoid receptor antagonists 1
Mineralocorticoid receptor antagonists should be considered in patients with heart failure and LV systolic
dysfunction [51,145].
Loop diuretics
Loop diuretics should be considered to treat symptoms of congestion in patients with heart failure [134,207].
Calcium channel blockers
Dihydropyridines2 should be considered for the treatment of angina [134,208].
Verapamil3 is recommended in patients with LVOT obstruction symptoms and should be considered in
patients with angina [51,145,208].
Diltiazem3 should be considered in patients with LVOT obstruction symptoms or angina [51,145,208].
Ivabradine 3
Ivabradine should be considered for the treatment of heart failure or angina, according to ESC
guidelines [145,207,208].
Antiplatelet therapy
Antiplatelet therapy should be started in patients who suffered a stroke or myocardial infarction [134].
Anticoagulation
Anticoagulation should be immediately started once atrial fibrillation or flutter is detected [145].
Direct oral anticoagulants (DOACs) should be considered as the first-line choice in patients without
contra-indications [145].
Anti-arrhythmic drugs
Amiodarone should be avoided in FD [213,214].
Dronedarone is contra-indicated in patients with heart failure (NYHA class III–IV) and renal failure
(eGFR < 30mL/min) [145].
Sotalol, flecainide and propafenone are contra-indicated in patients with heart failure [145].
Management of cardiovascular risk factors
Control of cardiovascular risk factors, including arterial hypertension, diabetes and dyslipidaemia, is
indicated [134].
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Table 7. Cont.
Recommendations for the Supportive Treatment of Cardiac Manifestations in FD
Pacemaker
Pacemaker may be required to treat symptomatic bradycardia or symptomatic/advanced cardiac blocks,
according to ESC guidelines [134,145].
Dual chamber pacemakers should be implanted unless patients are in permanent atrial fibrillation [145].
ICD
ICD implantation is recommended in patients who suffered sudden cardiac arrest due to VT/fibrillation or
sustained VT causing syncope/haemodynamic compromise and have a life expectancy >1 year [209].
ICD implantation should be considered in patients with advanced hypertrophy and fibrosis, who require
pacemaker implantation and have a life expectancy >1 year [145].
ICD implantation may be considered in patients with severe LVH and advanced fibrosis or non-sustained VT,
who have a life expectancy >1 year [145].
ICD implantation is recommended in patients with heart failure (NYHA class II-III) and LV ejection fraction
≤35%, despite ≥3 months of optimal treatment, who have a life expectancy >1 year [207].
CRT
CRT should be considered in patients with LV ejection fraction ≤35%, according to ESC guidelines [207].
CRT-P should be considered in symptomatic patients with a pacing indication, LV ejection fraction <50% and
QRS duration >120ms [145].
Septal reduction therapy (myectomy/alcohol ablation therapy)
Septal reduction therapy is recommended in patients with a resting or provoked LVOT gradient ≥50 mm Hg,
who are in NYHA class III–IV, despite maximum tolerated medical therapy [51,210,211].
Septal reduction therapy should be considered in patients with a resting or provoked LVOT gradient ≥50 mm Hg,
who suffer recurrent exertional syncope, despite maximum tolerated medical therapy [51,210,211].
Heart transplantation
Heart transplantation should be considered in patients with advanced heart failure with severe LV
dysfunction and NYHA class III–IV despite optimal medical therapy, or intractable ventricular arrhythmia,
depending on the extension of the extracardiac involvement by the disease [134,217].
CRT, Cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; ESC, European Society
of Cardiology; FD, Fabry disease; ICD, Implantable cardioverter-defibrillator; LV, left ventricular; LVH, left
ventricular hypertrophy; LVOT, left ventricular outflow tract; NYHA, New York Heart Association; VT, ventricular
tachycardia 1 Caution should be taken in Fabry patients with nephropathy due to the risk of hyperkalaemia or
worsening of renal function; 2 Should be avoided, if possible, in patients with resting/latent LVOT obstruction; 3
Caution should be taken due to the increased risk of bradycardia in Fabry patients.
6. Conclusions
Cardiac involvement remains the leading cause of death in Fabry patients. GB3 de-
posits are found in virtually all cardiac cells, but the mechanisms leading to organ damage
remain less defined. Fabry hearts exhibit myocardial hypertrophy, inflammation, apoptosis,
necrosis and fibrosis, valve thickening, and narrowing of intramural coronary arteries.
Cardiac manifestations therefore include LVH, heart failure, angina, valve disease, dys-
rhythmias, cardiac conduction blocks, and sudden cardiac death, and the severity of cardiac
involvement is the same either in classic or late-onset phenotypes.
ERT has demonstrated to reduce or stabilize LV mass and wall thickness and to
reduce the incidence and delay the occurrence of clinical events, whereas migalastat has
consistently shown to reduce LV mass. Early treatment has shown to achieve better
outcomes, while cardiac fibrosis is deemed to be irreversible. Still, evidence is lacking on
the efficacy of available therapies on hard-endpoints, such as total mortality, cardiovascular
mortality, heart failure, dysrhythmias, or need for a cardiac device, as well as in late-onset
phenotypes with predominant cardiac involvement. Furthermore, despite several therapies
targeting, the enzymatic defect or substrate accumulation are under research, it remains to
be clarified if other therapeutic strategies will be needed to avoid or revert cardiac damage
in FD.
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